SCHEMBL4138770

SCHEMBL4138770

Cc1nc2ccc(N3CCCCC3)cc2c(-c2ccc(F)cc2)c1C(C)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.43
TDO2 P48775 1/20 0.43
IDO2 Q6ZQW0 1/20 0.43
KDM4E B2RXH2 4/20 0.38
MAPT P10636 4/20 0.38
NPY5R Q15761 1/20 0.38
PSMB1 P20618 1/20 0.38
PSMB5 P28074 1/20 0.38
LMNA P02545 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
ALDH1A1 P00352 1/20 0.37
POLB P06746 1/20 0.37
HPGD P15428 1/20 0.37
PSIP1 O75475 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4146761 0.91 KDM4E (0.48) IDO1TDO2IDO2KDM4EMAPT
SCHEMBL27704120 0.84 PSIP1 (0.44) IDO1TDO2IDO2KDM4EMAPT
SCHEMBL4071227 0.84 IDO1 (0.40) IDO1TDO2IDO2KDM4EMAPT
SCHEMBL4139178 0.83 APP (0.41) IDO1TDO2IDO2KDM4EMAPT
SCHEMBL3971049 0.82 FGFR1 (0.41) IDO1TDO2IDO2KDM4E
SCHEMBL4071545 0.82 IDO1 (0.42) IDO1TDO2IDO2KDM4EMAPT
SCHEMBL13881532 0.82 IDO1 (0.38) IDO1TDO2IDO2KDM4EMAPT
SCHEMBL3965874 0.82 FABP3 (0.49) IDO1TDO2IDO2KDM4EMAPT
SCHEMBL3961778 0.82 IDO1 (0.44) IDO1TDO2IDO2KDM4EMAPT
SCHEMBL4147074 0.81 IDO1 (0.37) IDO1TDO2IDO2KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009041904-A1 QUINOLINE COMPOUNDS HAVING AN ACTIVITY AGAINST THE GABAB RECEPTOR ASTRAZENECA AB (SE) 2009-04-02 WO disclosed
WO-2009041904-A1 QUINOLINE COMPOUNDS HAVING AN ACTIVITY AGAINST THE GABAB RECEPTOR ASTRAZENECA AB (SE) 2009-04-02 WO disclosed
US-20090088441-A1 Quinoline Compounds ASTRAZENECA AB (SE) 2009-04-02 US disclosed
US-20090088441-A1 Quinoline Compounds ASTRAZENECA AB (SE) 2009-04-02 US disclosed
US-20090088441-A1 Quinoline Compounds ASTRAZENECA AB (SE) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088441-A1 Quinoline Compounds GABRB1, HRH2, GABRA5 IDO1 996/4885TDO2 2448/4885IDO2 1281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.